Kornimate/medical-research-clean huggingface dataset:
clinical usefulness of cortisol, antinuclear antibodies and high-sensitivity c-reactive protein in acute pancreatitis

Conditions: Acute Pancreatitis

Summary: acute pancreatitis (ap) is a potentially life-threatening disease with varying severity of presentation. nearly 60%-80% of all cases of ap in developed countries are attributable to either gallstone disease or alcohol abuse. the incidence is similar in both sexes, although alcohol abuse is the more common cause in men and gallstones is the more common cause in women.

severe acute pancreatitis is one of the most common acute abdomens in clinical practice. owing to its acute onset, rapid progress, and high mortality, it has become a hot clinical study spot and one of the toughest medical problems. markers of inflammation, such as high-sensitivity crp (hs-crp), are predictive of the severity of acute pancreatitis and may be useful in identifying patients with severe acute pancreatitis in the early phase after onset. antinuclear antibodies (ana) are important biomarkers for the autoimmune disorder. ana may contribute to the pathogenesis of pancreatitis and ana positivity is associated with the presence of autoimmune pancreatitis. cortisol is released into the blood due to stimulation of corticotrophin receptors in the adrenal cortex. thus, serum cortisol can be measured. although the association between serum levels of some inflammatory marker and acute pancreatitis revealed, the relationship between ana, cortisol, hs-crp and with the severity of acute pancreatic lesions have not evaluated yet.

Eligibility criteria:
inclusion criteria: * abdominal pain consistent with ap * serum amylase activity at least 3 times greater than the upper limit of normal * patients of age 18 years or more who are willing to participate in the study and give their consent for same. exclusion criteria: * patients with severe liver disease, pulmonary embolus, sepsis, and renal failure were excluded from the study.

Keywords: marker of inflammation high-sensitivity crp antinuclear antibodies cortisol
acripab- trial: anti coagulation regimen in high risk patients for bleeding

Conditions: Hematologic Diseases

Summary: to determine the safety/efficacy of bivallirudin vs unfractionated heparin (ufh) on top of dual antiplatelet therapy in patients with high tendency for bleeding during urgent and elective pci.


Eligibility criteria:
inclusion criteria: inclusion criteria (any of the following): * ≥75 years * creatinin clearance rate \< 60 ml per minute * anemia (hb 9-11 mg%) * hypertension: bp \> 180/95 mmhg but less than 210/110 m hg * diabetic pts * steroid treated pts * recent (within 6 weeks) non major surgery * pts with hematological disorders associated with tendency for bleeding like thrombocytopenia (platelets 50000-150000) included ttp; exclusion criteria: exclusion criteria: * age \< 18 year * acute stemi (primary pci)\* * rescue angioplasty \<12h after lytic therapy\* * active bleeding * s.c lmwh \< 8 hours or ufh \< 4 hours before pci * using iib /iiia as an upstream therapy before pci * pci which will be involved with obligatory iib /iiia therapy: (thrombotic complication, occlusive dissection) * inr\>1.5 on day of cathetrization * bolus of 600mg of clopidogrel before pci * current pregnancy or women in reproductive age without contraceptives * hypersensitivity to heparin or bivalirudin or its components \*(possible using iib/iiia)

Keywords: safety efficacy
fibroids and infertility - a study of the significance of removal of fibroids with regard to endometrial receptivity

Conditions: Leiomyoma, Uterine

Summary: we aim to explore some of the molecular factors that reduce fertility for women with leiomyomas, taking into account leiomyoma location, size, number and vascularity. tissue samples from the endometrium and leiomyomas will be obtained during the mid secretory phase before and 3-6 months after surgical excision for a comprehensive search for key molecular derangements.

baseline medical information and standard questionnaire to record symptoms are collected from all participants and a gynaecological examination and a 2d and 3d vaginal ultrasonography including saline infusion sonography (sis), if indicated, are performed. blood samples for the biobank for extraction of germ line dna and for identification of possible biomarkers are taken. the women with submucosal leiomyomas will undergo hysteroscopic myomectomy and the women with intramural leiomyomas will undergo myomectomy per laparoscopy or laparotomy. for the participants with intramural leiomyomas and the fertile/infertile controls, endometrial samples are taken with an endometrial suction curette in an outpatient setting at day 19-23 of the menstrual cycle. the endometrial sampling in the group of women with submucosal leiomyomas is being done during the hysteroscopic removal of the leiomyoma, also at day 19-23 of the menstrual cycle. 3-6 months after surgery, cycle day 19-23, endometrial samples will be taken from the women who have undergone myomectomy and ultrasound examination is being performed. the women with submucosal leiomyomas will undergo a second look hysteroscopy

Eligibility criteria:
inclusion criteria: * age: 18 to 40 years * presence of leiomyoma(s) * regular menstrual cycle (28 +/- 7 days) * having had at least 2 normal menstrual cycles after ending the treatment if previously treated with gnrh analogue * signed informed consent exclusion criteria: * no treatment indication (no symptoms and/or no desire for fertility) * contraindication for surgery * known endometriosis * known pcos * untreated hydrosalpinx * malignancy; gynaecological or other location * pre-malignant or malignant pap smear or endometrial biopsy * hormonal treatment including ulipristal acetat and levonorgestrel intrauterine device last three months before inclusion in the study * ongoing treatment with gnrh analogue * pregnancy last 3 months * ongoing lactation

Keywords: infertility endometrial receptivity leiomyoma fibroid
mfr versus pfs techniques on pain,range of motion and disability in chronic non specific low back pain.

Conditions: Chronic Non Specific Low Back Pain

Summary: to compare effect of myofascial release versus post facilitation stretch in term of pain ,range of motion and disability in chronic non specific low back pain in patients.


Eligibility criteria:
inclusion criteria: * male and female adults already diagnosed with lbp * between ages group of 40-55 years. exclusion criteria: * patients who had lbp originating from various pathologies, such as presence of * cord compression, * radiculopathy, * osteoporosis,

Keywords: chronic pain,myofascial release technique, postfacilitation stretch,technique and low back pain.
metabolic effects of melatonin in patients treated with second generation antipsychotics

Conditions: Second Generation Antipsychotic Induced Metabolic Adverse Effects

Summary: schizophrenia and bipolar disorder are frequently associated with an elevated risk for obesity, metabolic syndrome, diabetes mellitus, dyslipidemia and other metabolic disturbances. second generation antipsychotics (sga) have a demonstrated efficacy in acute and long term treatment of these disorders and are considered a first option on most treatment guidelines. unfortunately the use of sga is associated to drug induced weight gain, disturbed glucose and lipid regulation and an increase of cardiovascular risk and mortality as well as non- adherence to treatment. there are several hypotheses attempting to explain the complex pathways that lead to antipsychotic therapeutic effects and their accompanying adverse effects. recently, in animals receiving sga, melatonin prevented to a large extent the body weight increase, which indicates a possible role for biological rhythms in sga induced body weight accumulation. melatonin is a hormone secreted by the pineal gland that follows a circadian rhythm with an increased secretion in the middle of the night. this hormone acts importantly on the suprachiasmatic nucleus and other areas in the brain and periphery. thus melatonin is involved in a series of biological functions such as sleep regulation, blood pressure, regulation of circadian rhythms, mood, behavior, and more recently in the regulation of metabolic processes including insulin, leptin, and lipid regulation. given previous results in experimental animals, the purpose of the present study is to test the potential effect of melatonin in reducing or preventing some of the metabolic disturbances associated with sga


Eligibility criteria:
inclusion criteria: 1. men and non-pregnant, non-lactating women aged between 18 and 45 years; 2. dsm-iv-tr criteria for schizophrenia or bipolar disorder type i; 3. free of concomitant medical or neurological illness (as per review of systems and general physical examination); 4. free of dsm-iv current substance abuse or a history of substance dependence in the last six months; 5. who were initiated on continuous treatment with sga (clozapine, olanzapine, quetiapine or risperidone) for a period no greater than the last three months prior to their inclusion to the present study. exclusion criteria: 1. were diagnosed with hypertension, diabetes mellitus, dyslipidemia, thyroid disorders or hepatic illness; 2. had a history of hypersensitivity to melatonin; 3. exhibited high risk for suicide or high risk for aggressiveness; 4. women who were not practicing reliable forms of contraception. patients were eliminated from the study if they suspended sga or two consecutive doses of the study capsule at any point during the follow up period.

Keywords: melatonin second generation antipsychotic bipolar disorder schizophrenia metabolic
bariatric surgery study

Conditions: Depression; Quality of Life; Interpersonal Relations

Summary: the current study proposes an open clinical trial to investigate the effectiveness of a social functioning intervention on bariatric surgery outcomes and depression. the treatment will be administered in a group format over 10 weekly/biweekly sessions and will take place at the university of washington weight loss management clinic (wlmc) at the roosevelt clinic location. effects of the intervention will be measured with self-report questionnaires and by self-report of behaviors outside of assessment sessions (via questionnaires and self-report of adherence to treatment). data collection will occur at specific time points including before treatment, after treatment, and two months after treatment.

as of 2009, 344,000 bariatric procedures were performed annually . although some studies report depressive symptoms decrease in the 6 months after bariatric surgery, there is growing body of literature suggesting there exists a subgroup of patients whose depressive symptoms worsen after surgery and the likelihood of developing depressive symptoms increases longitudinally. depression can be an indicator of an increased risk of self-harm and additional studies have found that the risk of suicide may increase post bariatric surgery compared to obese individuals who have not undergone surgery. research supports that psychosocial factors contribute to successful postoperative outcomes. functional analytic psychotherapy shows potential to impact social variables that may be relevant to bariatric surgery outcomes including depression. in this context, fap aims to improve interpersonal relationships through experientially teaching skills intended to increase social connection. fap also seeks to increase awareness, which includes the ability to view interpersonal interactions from multiple perspectives, allowing new interpersonal skills to emerge. the present study seeks to evaluate the use of a fap group to enhance interpersonal relating with a sample of post-bariatric surgery patients. measures will be collected on quality of life and variables involved in interpersonal connectedness.

Eligibility criteria:
inclusion criteria: * older than 18 * speak english as a primary language * had bariatric surgery in the past 6-24 months (bypasses (roux-en-y) or sleeves) * yes to one or both of the first two phq-9 questions * not pregnant * not traveling anywhere in the next 6 months * no surgeries scheduled in the next 12 months exclusion criteria: • no exclusion criteria are utilized in the present study.
evaluation of the efficacy of the brainport vision pro on the performance of daily activities in the profoundly blind french population

Conditions: Blindness

Summary: the purpose of the study is to evaluate the effectiveness and safety of the brainport® vision pro, an electronic oral assistive device, in the performance of daily tasks by french persons who have residual vision limited to light perception or less in both eyes.


Eligibility criteria:
inclusion criteria: 1. 8 years of age or older 2. diagnosis of profound blindness with residual vision limited to a perception of light or lower in both eyes. 3. minimum post 12 months diagnosis of blindness 4. previously completed conventional rehabilitation such as orientation and mobility training with a cane or guide dog. 5. ability to be read and to understand the documentation and procedures of the study. 6. ability to provide feedback on the use of the brainport vision pro device. 7. ability to use basic computer and/or other technologies. 8. willing and able to answer all questionnaires, carry out telephone follow-ups, undergo device training and carry out all study procedures, after having passed the orientation phase with the device. 9. participant or his legal representative willing and able to sign informed consent. exclusion criteria: 1. ongoing oral disorders determined on the basis of the participant's medical history and/or by an examination of the oral cavity by a dental specialist. 2. history of tongue damage resulting in sensitivity problems or impaired language. 3. visible open sores, herpes, abrasions, blisters or rashes on the tongue or numbness of the tongue. 4. piercings on the tongue. 5. planned or recent oral surgery (in the last 3 months) and/or dental care (excluding oral check-ups or routine scaling). 6. known neuropathy of the language or sensory system. 7. history of seizures or epilepsy. 8. pregnant woman, willing to be pregnant or lactating. women of childbearing age should consent to the use of appropriate contraception to avoid pregnancy during the study period. 9. implanted medical devices (e.g., pacemaker, deep brain stimulation device, cochlear implant). 10. any hearing impairment that prevents you from hearing the device's announcements. 11. cognitive impairment detected on the basis of medical history and/or during a cognitive impairment telephone interview. 12. expected or ongoing participation in another clinical trial or any research that may interfere with this study. 13. known allergy to nickel, gold or a stainless-steel component. 14. any health condition that may interfere with the study's evaluations. 15. a person unable to assemble the device and/or interpret the device's signals or who refuses to continue to participate in the study after passing the initial training phase with the device. 16. person deemed unfit to participate in the study by the lead investigator for any other previously cited reason. 17. adults who do not have the ability to provide valid informed consent (under legal protection)

Keywords: blindness brainport brainport vision pro assistive device assistive technology visual impairment
a study of pentosan polysulfate sodium and the development of pigmentary maculopathy and pigmentary retinopathy

Conditions: Pigmentary Maculopathy; Pigmentary Retinopathy; Interstitial Cystitis

Summary: the purpose of this study is to evaluate incidence and prevalence rates of the study endpoints (pigmentary maculopathy \[pm\]/ pigmentary retinopathy \[pr\]/any, pm/pr/ pentosan polysulfate sodium \[pps\], and pm/pr/non-pps) in relation to pps exposure, and in participants with interstitial cystitis (ic) but not exposed to pps; changes in visual acuity (va) over time; participant treatment journey leading to pps treatment, and potential risk factors associated with the occurrence of pm/pr/pps.


Eligibility criteria:
inclusion criteria: * participants must have at least 6 months baseline information prior to index date (this may apply to the relevant databases, if the study participants are identified and the outcomes are ascertained via multiple linked data source) for the pentosan polysulfate sodium (pps) cohort * participants must have records in both the intelligent research in sight (iris) database and the closed claims portion of the komodo claims database and have at least one record of pps dispensing for the interstitial cystitis (ic) cohort not exposed to pps * participants must have records in both the iris database and the closed claims portion of the claims database; have at least one diagnosis of ic; and have no record of pps dispensing exclusion criteria: - evaluated based on the komodo database. participants will be excluded from the study if they have no information on age or sex (or both)
safety and efficacy of avapritinib in relapsed or refractory pediatric cbf-aml with kit mutation

Conditions: AML, Childhood; Relapse/Recurrence; Refractory AML; Core Binding Factor Acute Myeloid Leukemia; C-KIT Mutation

Summary: the purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with kit mutation.

this is a multicenter, single-arm, prospective, and intervention trial. about 30% of core binding factor acute myeloid leukemia (cbf-aml) patients still relapse under current treatment. some studies have found that kit mutations, especially the d816v mutation, may predict relapse and decrease overall survival (os) in cbf-aml. avapritinib has been approved for the treatment of gastrointestinal stromal tumors with kit or pdgfra mutations. avapritinib was also effective for the treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation in a single-center, retrospective report. 11 centers from china carry out the avacbfkit regimen including avapritinib, hypomethylating agents and low dose chemotherapy for the treatment of relapsed or refractory pediatric cbf-aml with kit mutation. the main focus of this study is to evaluate the efficacy and safety of avapritinib in the regimen.

Eligibility criteria:
inclusion criteria: 1. gender unlimited; 2. under 18 years; 3. diagnosis of acute myeloid leukemia (according to the 2022 who classification). 4. presence of t(8;21)/runx1::runx1t1 or inv(16)/t(16;16)/cbfβ::myh11; 5. kit mutation; 6. refractory aml: aml patients who do not achieve cr or cri after induction therapy; 7. relapsed aml: patients who achieved remission after consolidation therapy or transplantation, fish confirmed that the fusion gene turned positive, or extramedullary leukemia infiltration; 8. no active infections; 9. liver function: tbil ≤2×uln, alt/ast ≤3×uln, creatinine clearance ≥50ml/min; 10. ecog score \<2; 11. expected survival time \>12 weeks; 12. participants must have the ability to understand and be willing to participate in this study and must sign an informed consent form. exclusion criteria: 1. have received prior treatment with avapritinib; 2. receiving other targeted therapies for aml at the same time, such as dasatinib, sorafenib, gilteritinib, venetoclax, etc; 3. presence of active uncontrolled infection (including bacterial, fungal, or viral infection); 4. present of significant underlying organ diseases: such as myocardial infarction, chronic heart failure, decompensated liver or kidney dysfunction； 5. with other malignancies requiring treatment； 6. already enrolled in another interventional clinical study； 7. the researchers determined that the individual is not suitable to participate in this trial.

Keywords: avapritinib kit cbf aml childhood relapsed/refractory
hemodynamic assessment of healthy and hypertensive pregnant women by non-invasive bio-reactance

Conditions: Hypertension, Pregnancy-Induced

Summary: the purpose of this study is to determine whether a noninvasive method of measuring certain aspects of blood circulation (e.g., blood pressure, cardiac output) is an accurate and reliable method to detect changes in pregnant patients. specifically,the investigators are interested in patients diagnosed with high blood pressure during their pregnancy, as compared with normal pregnant patients. a noninvasive, accurate method of taking these measurements in pregnant patients is not currently available.

during pregnancy, many aspects of blood circulation, such as blood pressure, heart rate, cardiac output, and stroke volume, adapt to accommodate the increasing needs of a pregnant body. the circulatory system works harder to provide blood flow to the placenta and the growing fetus. currently, the devices that can give physicians detailed information on the status of the blood circulation of normal patients and those with high blood pressure during pregnancy are invasive to varying degrees. however, recently, a new noninvasive hemodynamic monitor (noninvasive cardiac output monitoring: nicom) was introduced to the market. in studies with non-pregnant patients, the nicom has been found to be accurate, precise and reliable. however, it has yet to be studied in the field of obstetrics. the purpose of this study is to find out if the nicom is an effective tool for monitoring hemodynamic changes in pregnant women, both with normal and high blood pressure. we are planning to compare the hemodynamic profiles of normal pregnant patients, hypertensive pregnant patients, and non pregnant patients as a control group. if this monitor proves to be reliable in assessing these changes in the pregnant patients, this could have a great impact in optimizing the care of the patients with different medical conditions in pregnancy, such as increased blood pressure.

Eligibility criteria:
inclusion criteria: * pih diagnosed in 3rd trimester, not yet treated * healthy pregnant patients in 3rd trimester * healthy non-pregnant women exclusion criteria: * under age 18 or above age 40 * refusal to participate

Keywords: pih pregnancy induced hypertension pregnancy bioimpedance noninvasive monitoring cardiac output blood pressure
a study comparing the efficacy and safety of idp-121 and idp-121 vehicle lotion in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: the primary objective of this study is to compare the efficacy, safety and tolerability of idp-121 lotion and vehicle in the treatment of subjects with acne vulgaris.

this is a multicenter, randomized, double-blind, parallel group, vehicle-controlled, 12-week study to evaluate relative changes in inflammatory and non-inflammatory lesion counts, as well as treatment success using an evaluator's global severity scale (egss) in subjects with moderate to severe acne. idp-121 is a lotion for the topical treatment of acne.

Eligibility criteria:
inclusion criteria: * male or female at least 9 years of age and older * written and verbal informed consent must be obtained. * subject must have a score of moderate or severe on the evaluator's global severity assessment at the screening and baseline visit * pre-menses females and women of childbearing potential must have a negative urine pregnancy test at the screening and baseline visits * subjects must be willing to comply with study instructions and return to the clinic for required visits. exclusion criteria: * any dermatological conditions on the face that could interfere with clinical evaluations * any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive * subjects with a facial beard or mustache that could interfere with the study assessments * concomitant use of potentially irritating over-the-counter products